Sumitomo Pharma America
55 Cambridge Parkway Suite 102W
Cambridge, MA 02142
United States
Tel: +1(508)481-6700
Website: https://www.us.sumitomo-pharma.com/
About Sumitomo Pharma America
Focus Areas
We tackle unmet patient needs in the crucial fields of psychiatry and neurology, oncology, urology, women's health, rare diseases, and cell and gene therapies.
Technology
We unlock innovative science and solutions through cutting-edge technology. Advanced in-house technology platforms and data analytics capabilities de-risk and optimize clinical and commercial programs to accelerate insights in science, research, and discovery.
Advocating for Patients
We reimagine what’s possible We see people as more than the conditions they are managing. We are unwavering in our promise to advocate for patients and their families on the things that matter most to them. This promise is central to everything we do as we pursue unprecedented medical innovation.
Heritage
We are building on a legacy With Sumitomo Pharma's 125-year legacy as our foundation, Sumitomo Pharma America was formed through the consolidation of Sumitomo Pharma’s US affiliates. Our parent company, the Sumitomo Group, is over 400 years old, with an extensive history of supporting health and wellbeing.
CONNECT
166 articles about Sumitomo Pharma America
-
Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on May 11, 2021
5/4/2021
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its fourth fiscal quarter and fiscal year 2020, ended March 31, 2021. The webcast and conference call will be held at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on May 11, 2021.
-
Clinical Catch-Up: April 12-16
4/19/2021
It was a particularly busy week for clinical trial news, in part because of several big medical conferences. Here’s a look. -
Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
4/12/2021
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 SERENE study evaluating the contraceptive efficacy of relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg)
-
Myovant Sciences Appoints Lauren Merendino as Chief Commercial Officer
4/5/2021
Myovant Sciences, a healthcare company focused on redefining care for women and for men, announced the appointment of Lauren Merendino as Chief Commercial Officer of Myovant Sciences, Inc., effective April 5, 2021.
-
Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorization Application for Relugolix for the Treatment of Advanced Prostate Cancer
3/29/2021
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for relugolix for the treatment of advanced prostate cancer.
-
Clinical Catch-Up: March 22-26
3/29/2021
There was a fair amount of clinical trial news last week. Here’s a look. -
Myovant Sciences and Pfizer announced positive results from the Phase III LIBERTY trial of relugolix combination therapy in women with uterine fibroids.
-
Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
3/24/2021
Myovant Sciences and Pfizer Inc. announced positive data from the Phase 3 LIBERTY randomized withdrawal study of relugolix combination therapy in women with uterine fibroids.
-
Myovant Sciences Announces Recipients of “Forward for Health Equity” Grants to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids
3/23/2021
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the four recipients of its Forward for Health Equity grants
-
Clarivate published its annual “Drugs to Watch” list, and cited four drugs that it expects to be blockbusters—projected to bring in $1 billion in sales annually.
-
Myovant Sciences to Present at Upcoming Investor Conferences - Feb 22, 2021
2/22/2021
Myovant Sciences, a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences
-
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 - Feb 17, 2021
2/17/2021
Myovant Sciences, a healthcare company focused on redefining care for women and for men, announced that it approved equity awards for 7 new employees with a grant date of February 16, 2021 pursuant to Myovant’s 2020 Inducement Plan.
-
Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
2/17/2021
LIBERTY 1 and LIBERTY 2 achieved 73.4% and 71.2% response rates in menstrual blood loss, with an average reduction of 84.3% from baseline Achieved six of seven key secondary endpoints including reduction of pain Bone mineral density maintained at levels comparable to placebo Data were included in U.S. New Drug Application for relugolix combination tablet for uterine fibroids
-
HealthyWomen and Myovant Sciences Launch “Voices of Periods” to Fight Menstrual Stigma
2/16/2021
HealthyWomen, the nation’s leading independent, nonprofit health information source for women, and Myovant Sciences, a healthcare company focused on redefining care for women and for men, launched “Voices of Periods,” a storytelling initiative to elevate conversations about menstrual health by sharing diverse, personal stories of the real-life impact of menstrual stigma.
-
Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal Year 2020
2/11/2021
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced corporate updates and financial results for the third quarter of fiscal year 2020.
-
Myovant Sciences to Host Third Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on February 11, 2021
1/29/2021
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its third fiscal quarter 2020, ended December 31, 2020.
-
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
1/26/2021
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 SPIRIT long-term extension study of the investigational once-daily relugolix combination therapy
-
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 - Jan 20, 2021
1/20/2021
Myovant Sciences, a healthcare company focused on redefining care for women and for men, announced that it approved equity awards to David Marek in connection with his previously-announced employment by Myovant Sciences, Inc. as its chief executive officer, which consisted of restricted stock units to acquire 223,076 common shares of Myovant Sciences Ltd., and an option to purchase 306,427 Myovant common shares.
-
BioSpace Movers & Shakers, Jan. 8
1/8/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
1/5/2021
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, chief executive officer of Myovant Sciences, Inc., will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 2:50 p.m. Pacific Time. A live webcast of the presentation will be accessible on the Events page under the Investors & Media section of the Myo